MESO Q2 2018 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+2315.1% YoY

Gross Profit

$12M94.0% margin

Operating Income

-$9M-69.8% margin

Net Income

$14M103.2% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

+1031.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$665M

Total Liabilities

$89M

Stockholders' Equity

$576M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$550,000	+2315.1%
Gross Profit	$12M	-$3M	+485.2%
Operating Income	-$9M	-$23M	+59.4%
Net Income	$14M	-$20M	+168.3%